BDX Stock Analysis — Becton Dickinson
Sector: Healthcare
AI Verdict
BDX trades at 12.4x next year's earnings with sky-high growth expectations, so you're getting a bargain if the moat delivers, but the numbers leave no room for disappointment.
Competitive Moat
Becton Dickinson dominates in medical devices and consumables, supplying critical products like syringes and diagnostic equipment to hospitals and labs globally. Its moat comes from entrenched relationships with healthcare providers and regulatory barriers that make it hard for new entrants to match its scale and reliability.
Summary
A huge swing in earnings expectations is driving attention, with forward EPS growth forecast at +337.8%.
Where It Stands
BDX has returned 19.38% over the past year, trades at 12.4x next year's earnings (well below the 22x healthcare sector median), and its RSI of 48.3 signals a cooling, neutral setup.
Key Metrics
- RSI: 48.3 — Neutral
- Trailing P/E: 54.4x
- Forward P/E: 12.4x
- PEG Ratio: 0.16
- Earnings Growth: +3.4%
- Revenue Growth: -0.0%
- Market Cap: $49.0B
- Dividend Yield: 0.02%
- 1-Year Return: 19.38%
- 52-Week High: $193.07
- 52-Week Low: $127.59
Analyst Consensus
12 Buy · 9 Hold · 0 Sell (21 analysts)
Bull Case
With analysts projecting a 337.8% jump in EPS, the current 12.4x forward P/E is cheap for the explosive growth expected if BDX executes.
Bear Case
If the forward P/E reverts closer to the 54.4x trailing multiple due to a miss on that 337.8% EPS growth, the stock could see a painful rerating.
Catalyst to Watch
Watch for quarterly earnings — a beat or miss on the massive earnings growth estimate will set the tone for valuation.